GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: The Journal of Pediatrics, Elsevier BV, Vol. 156, No. 1 ( 2010-1), p. 66-70.e1
    Type of Medium: Online Resource
    ISSN: 0022-3476
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2010
    detail.hit.zdb_id: 2005245-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 112, No. 11 ( 2008-11-16), p. 1414-1414
    Abstract: BABY HUG is an NHLBI/NICHD-sponsored Phase III randomized double-blinded placebo-controlled clinical trial (NCT00006400) to test the hypothesis that hydroxyurea can prevent chronic organ damage in very young children with sickle cell anemia (SCA). Renal and splenic function measures are the co-primary endpoints. Renal disease in SCA begins early in life with impaired urine concentration and acidification, along with glomerular hyperfiltration; some patients will progress to microalbuminuria, glomerulosclerosis, macroalbuminuria, and even renal failure. In BABY HUG, glomerular filtration rate (GFR) elevation was selected as a primary endpoint, to be measured quantitatively by plasma clearance of injected 99mTc-DTPA and also estimated by the Schwartz equation where GFR = (height × 0.55)/(serum creatinine), with creatinine measured by HPLC to .01 mg/dL precision. Of 233 enrolled subjects, 193 completed screening and were randomized to study treatment. Quantitative GFR measurement was successful in most cases: 176 of 182 (97%) of DTPA clearance studies were adequate and 157 subjects had both baseline DTPA and Schwartz GFR values available for analysis. The average age at GFR measurement was 13.7 ± 2.6 months (range 9–19 months) and 59% of subjects were female. Baseline mean (± 1SD) hematological parameters included hemoglobin = 9.0 ± 1.4 gm/dL, absolute reticulocytes = 295.3 ± 137.4 × 109/L, WBC = 14.3 ± 5.8 × 109/L, and fetal hemoglobin (HbF) = 25.6 ± 8.8%. Baseline past medical history included dactylitis (34%), splenic sequestration (7%), and acute chest syndrome (5%). The average baseline quantitative GFR measurement determined by DTPA clearance was elevated at 125.4 ± 34.4 mL/min/1.73m2, (range 40.2 – 300.9 mL/min/1.73m2, normal value 100 ± 20 mL/min/1.73m2). The average baseline GFR estimate by Schwartz equation was substantially higher at 193.9 ± 53.8 mL/min/1.73m2, range 65.8 – 350.0 mL/min/1.73m2. In univariate analysis, the DTPA GFR value was positively correlated with the Schwartz GFR estimate (r=0.22, p=0.0059, slope=0.145) as well as age, weight, height (all p≤.001) but not with hemoglobin, HbF, WBC, reticulocytes, previous sickle cell-related events, or measures of splenic function including liver-spleen scan and quantitation of pitted erythrocytes and micronuclei. The Schwartz GFR estimate was positively correlated with age, height, WBC, and splenic function, and negatively correlated with hemoglobin and HbF. Using a quantitative GFR threshold of 120 mL/min/1.73m2 and an age threshold of 15 months, higher GFR values were observed in older infants, p=0.026. These data indicate that renal dysfunction measured by GFR elevation may begin early in life in SCA; quantitative GFR measurement is feasible but highly variable in this very young patient population; (3) the Schwartz and DTPA GFR values are strongly correlated, but the Schwartz estimate is usually greater and only modestly agrees with the quantitative DTPA GFR value. These baseline GFR measurements in BABY HUG support the hypothesis of age- and disease-related glomerular hyperfiltration in SCA. BABY HUG should yield important information regarding the ability of hydroxyurea to prevent renal damage among infants with SCA.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Pediatric Blood & Cancer, Wiley, Vol. 51, No. 5 ( 2008-11), p. 643-646
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2008
    detail.hit.zdb_id: 2130978-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Pediatric Blood & Cancer, Wiley, Vol. 54, No. 2 ( 2010-02), p. 250-255
    Abstract: Evidence of the laboratory benefits of hydroxyurea and its clinical efficacy in reducing acute vaso‐occlusive events in adults and children with sickle cell anemia has accumulated for more than 15 years. A definitive clinical trial showing that hydroxyurea can also prevent organ damage might support widespread use of the drug at an early age. BABY HUG is a randomized, double‐blind placebo‐controlled trial to test whether treating young children ages 9–17 months at entry with a liquid preparation of hydroxyurea (20 mg/kg/day for 2 years) can decrease organ damage in the kidneys and spleen by at least 50%. Creation of BABY HUG entailed unique challenges and opportunities. Although protection of brain function might be considered a more compelling endpoint, preservation of spleen and renal function has clinical relevance, and significant treatment effects might be discernable within the mandated sample size of 200. Concerns about unanticipated severe toxicity and burdensome testing and monitoring requirements were addressed in part by an internal Feasibility and Safety Pilot Study, the successful completion of which was required prior to enrolling a larger number of children on the protocol. Concerns over recruitment of potentially vulnerable subjects were allayed by inclusion of a research subject advocate, or ombudsman. Finally, maintenance of blinding of research personnel was aided by inclusion of an unblinded primary endpoint person, charged with transmitting endpoint data and monitoring blood work locally for toxicity (ClinicalTrials.gov number, NCT00006400). Pediatr Blood Cancer 2010;54:250–255. © 2009 Wiley‐Liss, Inc.
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2010
    detail.hit.zdb_id: 2130978-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 112, No. 11 ( 2008-11-16), p. 1413-1413
    Abstract: A urine concentrating defect is quite common in sickle cell anemia (SCA), has its onset in early childhood, and may be reversible (with transfusion) until age 10 years. BABY HUG is an NHLBI-NICHD sponsored double-blind, placebo-controlled Phase III Clinical Trial (NCT00006400) designed to assess efficacy of hydroxyurea in preventing organ damage in young children with SCA (Hb SS or SβO thalassemia); primary endpoints are spleen function and glomerular filtration rate (GFR). Two hundred thirty-three infants, recruited without regard to disease severity, underwent eligibility screening. To assess urine concentrating ability as a secondary endpoint, parents were instructed to collect and save timed urine specimens from subjects after 4 to 10 hours of fluid deprivation (NPO) overnight for osmolality (OSM) determination. More prolonged deprivation was avoided due to safety concerns. A paired serum sample for OSM, urea nitrogen (BUN), and creatinine was obtained the next morning. All specimens were analyzed in a central laboratory. The analyses included 184 infants with a urine specimen and a reported period of fluid deprivation of at least four hours; 178 had concurrent sera. Mean age was 13.0±2.7 mo (range 7.5 – 17.9 mo) and mean duration of fluid deprivation was 7.4±2.4 hr (4–13 hr). Mean serum OSM was 286±6 mOsm/kg H2O and independent of age, height, weight, or duration NPO. Urine OSM (mean 410±152, median 433, range 58–794 mOsm/kg H2O) was significantly greater than serum osmolality (p & lt;0.0001) and correlated with duration NPO (p=0.001). One hundred forty-two infants (77.2%) concentrated urine (urine OSM & gt; [mean serum OSM + 1 SD]); twenty-two (12.0%) had urine/serum OSM ratio & gt; 2 and 54 (29.4%) had urine OSM & gt; 500 mOsm/L. In addition, five infants (2.7%) were isosthenuric (urine OSM within mean serum OSM ± 1 SD) and 37 (20.1%) hyposthenuric ( & gt; 1 SD below mean serum OSM) despite instructions to withhold fluid. Urine OSM was associated with increasing 99mTc-DTPA GFR (p=0.024) and BUN (p & lt;0.0001), but not with serum OSM, age, height, weight or serum creatinine. We conclude that even with a variable, often limited, fluid deprivation challenge, 75 percent of young infants with SCD were able to concentrate urine. We anticipate that at the end of each infant’s two-year study drug treatment period parents will be more successful in achieving the recommended fluid deprivation and urine collection and that differences in concentrating ability between those taking hydroxyurea and those taking placebo will be discernable.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Pediatric Blood & Cancer, Wiley, Vol. 54, No. 2 ( 2010-02), p. 265-268
    Abstract: A urine concentrating defect is quite common in sickle cell anemia, has its onset in early childhood, and may be reversible with transfusion. The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) is a double‐blind, placebo‐controlled trial to assess efficacy of hydroxyurea in preventing organ damage in young children with sickle cell anemia. Procedures Enrolled infants were subjected to parent‐supervised fluid deprivation, and urine and serum osmolality were determined. Results Of 185 infants age 7.5–17.9 months (mean 13.0 ± 2.7) and fluid‐deprived 7.4 ± 2.4 hr (range 4–13), 178 had concurrent determinations of urine and serum osmolality. Mean serum osmolality was 286 ± 6 mOsm/kg H 2 O (range 275–312) and independent of age, height, weight, or duration of fluid deprivation. Urine osmolality (mean 407 ± 151, range 58–794 mOsm/kg H 2 O) was greater than serum ( P   〈  0.0001) and correlated with duration of fluid deprivation ( P  = 0.001). Of 142 (77.2%) who concentrated urine, 54 (29.4%) had urine osmolality 〉 500 mOsm/kg H 2 O. Urine osmolality correlated with 99m Tc‐DTPA clearance ( P  = 0.02) and serum urea nitrogen ( P   〈  0.0001), but not with serum osmolality, gender, age, height, weight, or serum creatinine. Infants able to produce urine with osmolality 〉 500 mOsm/kg H 2 O had higher mean fetal hemoglobin concentrations than did those who could not ( P  = 0.014). Conclusions Even with often limited fluid deprivation, 77.2% of young infants with sickle cell anemia were able to concentrate urine. Preservation of concentrating ability was associated with higher fetal hemoglobin concentration. Assessment will be repeated after 2 years of hydroxyurea or placebo treatment (ClinicalTrials.gov number, NCT00006400). Pediatr Blood Cancer 2010;54:265–268. © 2009 Wiley‐Liss, Inc.
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2010
    detail.hit.zdb_id: 2130978-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: American Journal of Roentgenology, American Roentgen Ray Society, Vol. 196, No. 6 ( 2011-06), p. 1399-1404
    Type of Medium: Online Resource
    ISSN: 0361-803X , 1546-3141
    RVK:
    RVK:
    Language: English
    Publisher: American Roentgen Ray Society
    Publication Date: 2011
    detail.hit.zdb_id: 2012224-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Pediatric Blood & Cancer, Wiley, Vol. 54, No. 2 ( 2010-02), p. 260-264
    Abstract: Subject retention and adherence are essential to maintain the power and validity of the Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG). We designed a study to assess adherence with study medication administration and study visits and to evaluate socioeconomic factors (SES) that may influence these measurements of adherence. These data are important for assessing impact of adherence on BABY HUG trial outcome and defining impact of SES on adherence. Methods Each subject's median study medication (MedAd) and mean visit adherence (VAd) were evaluated. We examined associations of adherence with SES of participating families. Results MedAd data were available on 153 of the 191 subjects who started randomized study medication. MedAd was 101.7% of volume prescribed, with 88.9% of subjects taking at least 80% of doses. VAd data were available on 185 of the 191 subjects who started randomized study medication. VAd was 97.3%, with 82.2% of subjects having no missed visits. During dose titration, subjects had on average 12.9% higher medication adherence than subjects who were on a stable dose and had less frequent study visits. MedAd and VAd were not significantly associated with SES. Conclusion Subjects in the BABY HUG trial have had excellent adherence. SES was not associated with adherence, suggesting that SES should not be used as a criterion for enrolment in clinical trials. Additional efforts are needed to maintain medication adherence, particularly when the interval between scheduled visits increases. (ClinicalTrials.gov number, NCT00006400). Pediatr Blood Cancer 2010;54:260–264. © 2009 Wiley‐Liss, Inc.
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2010
    detail.hit.zdb_id: 2130978-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Pediatric Blood & Cancer, Wiley, Vol. 54, No. 2 ( 2010-02), p. 256-259
    Abstract: Transcranial Doppler ultrasonography (TCD) is used to predict stroke risk in children with sickle cell anemia (SCA), but has not been adequately studied in children under age 2 years. Procedure TCD was performed on infants with SCA enrolled in the BABY HUG trial. Subjects were 7–17 months of age (mean 12.6 months). TCD examinations were successfully performed in 94% of subjects (n = 192). Results No patient had an abnormal TCD as defined in the older child (time averaged maximum mean TAMM velocity ≥200 cm/sec) and only four subjects (2%) had velocities in the conditional range (170–199 cm/sec). TCD velocities were inversely related to hemoglobin (Hb) concentration and directly related to increasing age. Conclusion Determination of whether the TCD values in this very young cohort of infants with SCA can be used to predict stroke risk later in childhood will require analysis of exit TCD's and long‐term follow‐up, which is ongoing (ClinicalTrials.gov number, NCT00006400). Pediatr Blood Cancer 2010;54:256–259. © 2009 Wiley‐Liss, Inc.
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2010
    detail.hit.zdb_id: 2130978-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 112, No. 11 ( 2008-11-16), p. 1416-1416
    Abstract: The Pediatric Hydroxyurea [HU] Phase III Clinical Trial [BABY HUG] , an NHLBI and NICHD sponsored double-blind placebo-controlled 14 center trial (NCT00006400), was designed to critically assess the efficacy of HU in preventing chronic organ damage in infants with sickle cell anemia [SCA]. The spleen is among the first organs damaged in SCA, but loss of function is variable among patients and difficult to measure. Pretreatment splenic filtrative function as determined by uptake on 99mTc sulfur colloid liver-spleen [LS] scan was compared to surrogate markers of spleen function: pocked erythrocyte [PIT] counts and flow cytometric quantitation of Howell-Jolly Bodies [HJB] . Splenic uptake of 99mTc sulfur-colloid was qualitatively interpreted by structured consensus of 3 pediatric nuclear medicine physicians. Results were correlated with age, total hemoglobin [Hb], fetal hemoglobin[HbF] , white blood cell [WBC], platelet [PLT] , absolute neutrophil count [ANC], reticulocyte count [RETIC] , spleen volume [SVOL] on ultrasound, maximum TCD velocity [TCD] , glomerular filtration rate determined by 99mTc-DTPA [GFR], steady state oxygen saturation [O2] , as well as clinical features of SCA (presence of a palpable spleen at screening, history of splenic sequestration, dactylitis, other vaso-occlusive event or transfusion). A logarithmic transformation was applied to each parameter (except age) to improve linearity with other variables and stabilize the variance of the transformed data. LS scans were available for 205 (89 male; mean age 13 mos, range 8–18 mos) of the 233 subjects who were recruited without regard to disease severity. To date 170 scans have been adjudicated into 1 of 3 categories of uptake: normal (n=21, 12.4%), reduced (n=124, 72.9%) and absent (n=25, 14.7%). Both surrogate markers of spleen function, PIT and HJB, increased with decreasing splenic function [p & lt;.001] and correlated well with each other [R2=.57, p & lt;.001]. Patients with absent splenic uptake had a significantly higher mean age (14.6 mos) than those with normal (12.3 mos) or reduced uptake (12.5 mos) [p=.001] . Higher PIT, HJB, WBC, RETIC, TCD and lower Hb or HbF values were significantly associated with decreased LS scan uptake [p & lt;.001]. PLT [p=.002] and ANC [p=.02] were also differentiated by categorical spleen function, while DTPA and O2 were not. SVOL was also not associated with spleen function as assessed by LS scan, PIT, or HJB, but was associated with a palpable spleen at screening [p=.001] . Patients with diminished spleen function on LS scan were more likely to have a history of splenic sequestration [p=.027], dactylitis [p=.025] , transfusion [p=.014], and vaso-occlusive events [p=.005] . Higher PIT and HJB values were associated with a history of splenic sequestration [p≤.001], palpable spleen at screening [p≤.003] and transfusion [p & lt;.001]. No child with a normal spleen scan had a palpable spleen at screening or a history of splenic sequestration or transfusion. This is the largest structured assessment of spleen function in SCA reported to date. Baseline data from the BABY HUG trial confirms that loss of spleen function begins in the first year of life and is associated with indicators of disease severity such as lower Hb and HbF, higher WBC, and history of splenic enlargement. We conclude that a palpable spleen may not be a functional one, and that spleen volume is unrelated to function. Surrogate assessments, PIT and HJB, correlate well with LS scan results and may obviate the need for radionuclide exposure to determine splenic function. With these 3 methods to assess spleen function the BABY HUG trial is well positioned to determine whether HU impacts the loss of spleen function and the utility of surrogate markers to monitor that effect.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...